Form 8-K ENANTA PHARMACEUTICALS For: Feb 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Enanta Pharmaceuticals (ENTA) PT Raised to $82 at Baird
February 8, 2018 6:43 AM ESTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $82.00 (from $46.00) while maintaining a Neutral rating on strong Hep C royalties/pipeline progress.
... More